Ambry Genetics Gains NYS Approval for Paired RNA, DNA Genetic Test

  • Jan 7, 2020

Ambry Genetics announced that its +RNAinsight combined DNA-RNA genetic test for hereditary cancer syndromes has received approval from the New York State Clinical Laboratory Evaluation Program (CLEP). The +RNAinsight test, which was launched in October, enables clinicians to conduct both DNA and RNA genetic testing at the same time, with the aim of returning more specific results to...

Read


Congress Passes LAB Act

  • Jan 7, 2020

Congress on Thursday passed the Laboratory Access for Beneficiaries (LAB) Act as part of an end-of-year spending packageThe bill, which will delay by one year the reporting of lab payment data required by the Protecting Access to Medicare Act (PAMA), will now be passed on to the President, who is expected to sign it into law. The LAB Act has been a priority for industry groups like...

Read


Palmetto Issues Final LCD for DermTech Pigmented Lesion Assay

  • Jan 7, 2020

Dermatology genomics testing company DermTech recently said that Medicare Administrative Contractor Palmetto GBA MolDx had issued a final local coverage determination for the company's Pigmented Lesion Assay (PLA). The LCD will take effect on Feb. 10, 2020, Palmetto said. The MAC issued a draft LCD for PLA in March 2019, proposing to cover the non-invasive RNA gene expression test...

Read


Calendar Year (CY) 2020 Annual Update for Clinical Laboratory Fee Schedule and Laboratory Services Subject to Reasonable Charge Payment

  • Jan 7, 2020

Based on Section 1833(h)(2)(A)(i) of the Act, available at https://www.ssa.gov/OP_Home/ssact/title18/1833.htm, the annual update to the local clinical laboratory fees for CY 2020 is 0.90 percent. Beginning January 1, 2020, this update applies only to pap smear tests. For a pap smear test, Section 1833(h)(7) of the Act requires payment to be the lesser of the local fee or the National Limitation...

Read


BCN to Deny Claims for Unauthorized Outpatient Toxicology Lab Services by Non-JVHL Labs Starting January 1st

  • Jan 7, 2020

Blue Care Network will deny claims for outpatient toxicology laboratory services provided by an out-of-network laboratory without authorization from Joint Venture Hospital Laboratories, starting Jan. 1. This applies to BCN HMOSM (commercial) claims. BCN contracts with JVHL to provide the statewide provider network for all outpatient laboratory services. This means: • Claims for outpatient...

Read


UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

  • Jan 7, 2020

Researchers from the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer.  The researchers used Guardant Health's liquid biopsy assay and Bio-Rad Technologies' droplet...

Read


Site-Neutral Back Pay: CMS to Give Hospitals More Money for 2019, Carry Fight Into 2020

  • Jan 7, 2020

The administration agreed to comply with a federal judge's order that vacated site-neutral payment provisions of OPPS 2019, but it appealed her decision and will keep pushing for related provisions in OPPS 2020. Officials have decided to do three things: (1) issue back payments to hospitals that endured rate reductions in 2019 due to the site-neutral payment policy, (2) appeal Collyer's...

Read


CMS Approves CAP's Pathologists Quality Registry

  • Jan 7, 2020

The College of American Pathologists said on Monday that the Centers for Medicare & Medicaid Services has approved its Pathologists Quality Registry as a qualified data registry to help pathology practices comply with requirements under Medicare’s Quality Payment Program and Merit-Based Incentive Payment System (MIPS). Qualifying pathologists face penalties from CMS for not reporting MIPS...

Read